Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07453238 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata

Study acronym: CALISTA-AA
StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Oct 1, 2026 → Mar 1, 2027
See other at-risk trials from Hayat Abad Medical Complex, Peshawar

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Start date: Apr 1, 2026 to Oct 1, 2026 Show 4 more changesShow less
    • Primary and study completion pushed from Oct 1, 2026 to Mar 1, 2027
    • Eligibility criteria expanded, about 11 words
    • Study description revised
    • Publications: details revised at 4 of 4 entries
  2. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized controlled trial compares the effectiveness of topical calcipotriol and intralesional corticosteroids in the treatment of alopecia areata. Alopecia areata is an autoimmune condition that causes non-scarring hair loss and can significantly affect quality of life. Intralesional corticosteroids are commonly used as first-line therapy; however, response rates vary and treatment may be associated with discomfort and local adverse effects. Sixty adult patients with patchy alopecia areata involving less than 50% of the scalp were randomly assigned to receive either topical calcipotriol or intralesional corticosteroid injections for 12 weeks. Participants were evaluated at four-week intervals. Treatment response was assessed using the Severity of Alopecia Tool (SALT) score and percentage improvement from baseline. The primary objective is to compare reduction in SALT score between the two treatment groups. Secondary outcomes include overall treatment efficacy and safety. The findings aim to determine whether topical calcipotriol provides superior or comparable clinical benefit to intralesional corticosteroids in patients with alopecia areata.
Trial Details
NCT Number NCT07453238
Lead Sponsor Hayat Abad Medical Complex, Peshawar
Conditions
(from sponsor)
Alopecia Areata
Related terms Alopecia Areata, Diffuse alopecia
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov